Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions
Lim-Fat M, Bennett J, Ostrom Q, Touat M, Franceschi E, Schulte J, Bindra R, Fangusaro J, Dhall G, Nicholson J, Jackson S, Davidson T, Calaminus G, Robinson G, Whittle J, Hau P, Ramaswamy V, Pajtler K, Rudà R, Foreman N, Hervey-Jumper S, Das S, Dirks P, Bi W, Huang A, Merchant T, Fouladi M, Aldape K, Van den Bent M, Packer R, Miller J, Reardon D, Chang S, Haas-Kogan D, Tabori U, Hawkins C, Monje M, Wen P, Bouffet E, Yeo K. Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions. Neuro-Oncology 2024, noae186. PMID: 39441704, DOI: 10.1093/neuonc/noae186.Peer-Reviewed Original ResearchSociety for Neuro-OncologyCentral nervous systemTumor typesCentral nervous system germ cell tumorsCare of AYA patientsManagement of CNS tumorsBrain tumorsCause of cancer-related deathCentral nervous system tumorsAdvanced molecular testingGerm cell tumorsUnique tumor biologyNervous system tumorsCancer-related deathsMalignant brain tumorsHistological diagnosisYoung adultsWHO classificationAYA populationCell tumorsCNS tumorsTargeted therapyTumor biologyAYA patientsConsensus reviewExploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors
Murray M, Noronha K, Wang Y, Friedman A, Paradkar S, Suh H, Sundaram R, Brenner C, Saltzman W, Bindra R. Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors. Molecular Cancer Therapeutics 2024, 23: 1176-1187. PMID: 38691846, PMCID: PMC11292319, DOI: 10.1158/1535-7163.mct-24-0012.Peer-Reviewed Original ResearchConvection-enhanced deliveryCentral nervous systemTreatment of primary central nervous systemPrimary central nervous systemSustained drug release in vitroTumor growth delayAssociated with lower survival ratesBone marrow suppressionComplex mutational profilesNAMPT inhibitorsRelease in vitroIntracranial GBM xenograftsBlood-brain barrierDrug release in vitroRetinal toxicityMarrow suppressionNAMPTiGrowth delayTherapeutic vulnerabilitiesExtended survivalLow survival rateGBM xenograftsMutation profilesPromoter methylationAnticancer activity in vitro